- Home
- CYRX vs PROK Comparison
CYRX vs PROK Comparison
Compare CYRX & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CYRX | PROK |
|---|---|---|
| Founded | 1999 | 2015 |
| Country | United States | United States |
| Employees | 1100 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 419.3M | 416.6M |
| IPO Year | 2008 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CYRX | PROK |
|---|---|---|
| Price | $15.49 | $1.52 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 5 |
| Target Price | ★ $13.31 | $7.40 |
| AVG Volume (30 Days) | 747.6K | ★ 1.6M |
| Earning Date | 05-04-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 156.22 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $176,177,000.00 | $893,000.00 |
| Revenue This Year | $11.06 | N/A |
| Revenue Next Year | $8.45 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 1075.00 |
| 52 Week Low | $6.69 | $1.48 |
| 52 Week High | $16.89 | $3.55 |
Technical Indicators
Market Signals| Indicator | CYRX | PROK |
|---|---|---|
| Relative Strength Index (RSI) | 48.83 | 34.77 |
| Support Level | $14.51 | N/A |
| Resistance Level | $16.76 | $2.59 |
| Average True Range (ATR) | 0.80 | 0.10 |
| MACD | -0.08 | -0.03 |
| Stochastic Oscillator | 40.09 | 2.54 |
Price Performance
Historical ComparisonAbout CYRX CryoPort Inc.
CryoPort Inc is a provider of integrated, temperature-controlled supply chain solutions for the life sciences industry, with a focus on supporting the cell and gene therapy market. The company provides services such as temperature-controlled logistics, biostorage, bioservices, cryopreservation solutions, and cryogenic systems manufacturing. It operates through two reportable segments: Life Sciences Services and Life Sciences Products. It generates the majority of its revenue from the Life Sciences Services segment.
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company pioneering the development of a first-in-class, autologous cell therapy that is intended to preserve kidney function in patients with advance chronic kidney disease (CKD) and diabetes. Its product candidate, REACT (Renal Autologous Cell Therapy), is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.